Neurocrine Biosciences Earnings Estimate

NBIX Stock  USD 115.90  3.21  2.69%   
The next projected EPS of Neurocrine Biosciences is estimated to be 1.3871 with future projections ranging from a low of 0.91 to a high of 1.82. Neurocrine Biosciences' most recent 12-month trailing earnings per share (EPS TTM) is at 3.29. Please be aware that the consensus of earnings estimates for Neurocrine Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Neurocrine Biosciences is projected to generate 1.3871 in earnings per share on the 31st of March 2025. Neurocrine Biosciences earnings estimates show analyst consensus about projected Neurocrine Biosciences EPS (Earning Per Share). It derives the highest and the lowest estimates based on Neurocrine Biosciences' historical volatility. Many public companies, such as Neurocrine Biosciences, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Neurocrine Biosciences Revenue Breakdown by Earning Segment

By analyzing Neurocrine Biosciences' earnings estimates, investors can diagnose different trends across Neurocrine Biosciences' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about 2.4 B in 2025. Pretax Profit Margin is likely to rise to 0.22 in 2025
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Neurocrine Biosciences Earnings Estimation Breakdown

The calculation of Neurocrine Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Neurocrine Biosciences is estimated to be 1.3871 with the future projection ranging from a low of 0.91 to a high of 1.82. Please be aware that this consensus of annual earnings estimates for Neurocrine Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
1.69
0.91
Lowest
Expected EPS
1.3871
1.82
Highest

Neurocrine Biosciences Earnings Projection Consensus

Suppose the current estimates of Neurocrine Biosciences' value are higher than the current market price of the Neurocrine Biosciences stock. In this case, investors may conclude that Neurocrine Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Neurocrine Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
2653.44%
1.69
1.3871
3.29

Neurocrine Biosciences Earnings per Share Projection vs Actual

Actual Earning per Share of Neurocrine Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Neurocrine Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Neurocrine Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Neurocrine Biosciences Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Neurocrine Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Neurocrine Biosciences should always be considered in relation to other companies to make a more educated investment decision.

Neurocrine Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Neurocrine Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-05
2024-12-311.92951.69-0.239512 
2024-10-30
2024-09-301.511.24-0.2717 
2024-08-01
2024-06-301.050.63-0.4240 
2024-05-01
2024-03-311.010.42-0.5958 
2024-02-07
2023-12-311.151.440.2925 
2023-10-31
2023-09-300.970.82-0.1515 
2023-08-01
2023-06-300.780.950.1721 
2023-05-03
2023-03-310.13-0.79-0.92707 
2023-02-06
2022-12-311.160.88-0.2824 
2022-11-01
2022-09-300.790.69-0.112 
2022-08-04
2022-06-300.6-0.18-0.78130 
2022-05-04
2022-03-310.350.14-0.2160 
2022-02-11
2021-12-310.52-0.08-0.6115 
2021-11-01
2021-09-300.60.640.04
2021-08-03
2021-06-300.480.43-0.0510 
2021-05-05
2021-03-310.510.33-0.1835 
2021-02-04
2020-12-310.540.720.1833 
2020-11-09
2020-09-300.22-0.62-0.84381 
2020-08-03
2020-06-300.730.810.0810 
2020-05-06
2020-03-310.540.39-0.1527 
2020-02-04
2019-12-310.750.35-0.453 
2019-11-04
2019-09-300.640.56-0.0812 
2019-07-29
2019-06-300.110.540.43390 
2019-04-29
2019-03-31-0.92-1.12-0.221 
2019-02-05
2018-12-310.180.190.01
2018-11-05
2018-09-300.460.520.0613 
2018-07-31
2018-06-30-0.17-0.070.158 
2018-04-30
2018-03-31-0.3-0.47-0.1756 
2018-02-13
2017-12-310.180.07-0.1161 
2017-11-01
2017-09-30-0.48-0.130.3572 
2017-08-03
2017-06-30-0.66-0.68-0.02
2017-05-09
2017-03-31-0.74-0.9-0.1621 
2017-02-14
2016-12-31-0.56-0.510.05
2016-11-02
2016-09-30-0.57-0.430.1424 
2016-08-03
2016-06-30-0.49-0.460.03
2016-05-05
2016-03-31-0.28-0.220.0621 
2016-02-11
2015-12-31-0.32-0.34-0.02
2015-10-29
2015-09-30-0.25-0.4-0.1560 
2015-07-29
2015-06-30-0.29-0.280.01
2015-04-30
2015-03-31-0.3-0.010.2996 
2015-02-09
2014-12-31-0.24-0.26-0.02
2014-11-03
2014-09-30-0.21-0.210.0
2014-08-06
2014-06-30-0.18-0.180.0
2014-04-30
2014-03-31-0.19-0.170.0210 
2014-02-06
2013-12-31-0.17-0.160.01
2013-10-29
2013-09-30-0.2-0.170.0315 
2013-07-25
2013-06-30-0.19-0.180.01
2013-05-02
2013-03-31-0.18-0.180.0
2013-02-08
2012-12-31-0.080.140.22275 
2012-10-31
2012-09-30-0.05-0.050.0
2012-07-31
2012-06-30-0.03-0.010.0266 
2012-05-02
2012-03-31-0.01-0.010.0
2012-02-08
2011-12-310.020.020.0
2011-10-31
2011-09-300.190.560.37194 
2011-07-28
2011-06-300.060.04-0.0233 
2011-05-03
2011-03-310.050.050.0
2011-02-10
2010-12-310.040.040.0
2010-10-28
2010-09-300.050.060.0120 
2010-07-28
2010-06-30-0.17-0.090.0847 
2010-04-28
2010-03-31-0.24-0.190.0520 
2010-02-03
2009-12-31-0.27-0.20.0725 
2009-10-28
2009-09-30-0.35-0.210.1440 
2009-07-29
2009-06-30-0.4-0.390.01
2009-05-05
2009-03-31-0.39-0.51-0.1230 
2009-02-03
2008-12-31-0.5-0.75-0.2550 
2008-10-28
2008-09-30-0.51-0.460.05
2008-07-30
2008-06-30-0.52-0.55-0.03
2008-04-30
2008-03-31-0.55-0.550.0
2008-02-05
2007-12-31-0.85-0.89-0.04
2007-11-01
2007-09-30-0.78-0.720.06
2007-07-31
2007-06-30-0.73-0.690.04
2007-05-03
2007-03-31-0.66-0.68-0.02
2007-02-01
2006-12-31-0.76-0.390.3748 
2006-11-02
2006-09-30-0.91-1.03-0.1213 
2006-07-17
2006-06-30-0.72-0.73-0.01
2006-04-24
2006-03-31-0.63-0.69-0.06
2006-01-23
2005-12-31-0.7-0.650.05
2005-10-24
2005-09-300.480.680.241 
2005-08-03
2005-06-30-0.24-0.150.0937 
2005-04-28
2005-03-31-0.64-0.510.1320 
2005-02-10
2004-12-31-0.35-0.57-0.2262 
2004-11-01
2004-09-30-0.39-0.050.3487 
2004-07-28
2004-06-30-0.27-0.31-0.0414 
2004-05-03
2004-03-31-0.36-0.350.01
2004-01-29
2003-12-31-0.140.090.23164 
2003-11-03
2003-09-30-0.36-0.310.0513 
2003-07-24
2003-06-30-0.38-0.330.0513 
2003-04-29
2003-03-31-0.38-0.43-0.0513 
2003-02-03
2002-12-31-0.85-1.27-0.4249 
2002-10-30
2002-09-30-0.81-0.660.1518 
2002-07-30
2002-06-30-0.68-0.650.03
2002-04-29
2002-03-31-0.66-0.520.1421 
2002-02-05
2001-12-31-0.5-0.53-0.03
2001-11-01
2001-09-30-0.30.090.39130 
2001-07-31
2001-06-30-0.62-0.520.116 
2001-04-30
2001-03-31-0.56-0.450.1119 
2001-01-30
2000-12-31-0.41-0.290.1229 
2000-11-02
2000-09-30-0.13-0.37-0.24184 
2000-07-28
2000-06-30-0.17-0.24-0.0741 
2000-04-27
2000-03-31-0.37-0.280.0924 
2000-02-14
1999-12-31-0.25-0.190.0624 
1999-11-01
1999-09-30-0.23-0.230.0
1999-08-03
1999-06-30-0.22-0.24-0.02
1999-05-05
1999-03-31-0.09-0.22-0.13144 
1999-03-05
1998-12-310-0.18-0.18
1998-11-02
1998-09-30-0.19-0.22-0.0315 
1998-08-04
1998-06-30-0.17-0.140.0317 
1998-05-04
1998-03-31-0.04-0.07-0.0375 
null
nullnullnullnull
1997-10-31
1997-09-300.050.060.0120 
1997-07-31
1997-06-30-0.020.010.03150 
1997-04-24
1997-03-310.120.230.1191 
1997-02-03
1996-12-310.210.240.0314 
1996-11-04
1996-09-300.03-0.02-0.05166 
1996-07-31
1996-06-300.040.110.07175 

About Neurocrine Biosciences Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Neurocrine Biosciences earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Neurocrine Biosciences estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Neurocrine Biosciences fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings29.2 M30.7 M
Retained Earnings Total Equity-366.1 M-384.4 M
Earnings Yield 0.02  0.03 
Price Earnings Ratio 40.15  42.16 
Price Earnings To Growth Ratio 1.22  2.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.